

Date: 24<sup>th</sup> March, 2023

To,  
The Manager,  
Department of Corporate Services,  
BSE Limited  
P. J. Towers, Dalal Street,  
Fort, Mumbai – 400 001  
Scrip Code:533573

To,  
The Manager,  
Listing Department,  
National Stock Exchange of India Ltd.  
'Exchange Plaza', Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051  
NSE Symbol: APLLTD

Dear Sir / Madam,

**Sub: USFDA inspection at Alembic Pharmaceuticals' Injectable Facility (F-3) at Karakhadi**

We would like to inform that the United States Food and Drug Administration (USFDA) has conducted an inspection at Alembic Pharmaceuticals' Injectable and Ophthalmic Facility (F-3) located at Karkhadi from 16<sup>th</sup> March, 2023 to 24<sup>th</sup> March, 2023. The USFDA issued a Form 483 with 2 minor procedural observations.

None of the observations are related to data integrity and management believes that they are addressable.

The Company is preparing the response to the observations, which will be submitted to the USFDA within stipulated period.

The Company is committed to maintain the highest quality standards and compliance at all times.

We request you to kindly take the same on record.

Thanking you,

Yours faithfully,

**For Alembic Pharmaceuticals Limited**

**R. K. Baheti**

**Director-Finance & CFO**

**ALEMBIC PHARMACEUTICALS LIMITED**